Hollister Biosciences Inc. Announces Exclusive Distribution Partnership with Nabis for Expanded Market Reach Across California

 
 

   Hollister leverages California's largest dispensary network and Nabis' rapid order fulfillment for its brand portfolio  

 

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company ", " Hollister Cannabis Co. " or " Hollister ") has partnered with one of California's leading distributors, Nabis, as demand for Hollister products continues to build. The new exclusive partnership will help streamline sales, grow retail opportunities and reduce wholesale delivery times on all orders.

 

Nabis supports California's cannabis market with its wholesale distribution services. Supplying more than 99% of California's dispensaries with a diverse selection of innovative products, Nabis works directly with brands to ensure timely fulfillment, and provides actionable sales data and insights to help brands scale and grow.

 

The partnership comes at a time when Hollister's portfolio of products continues to gain brand awareness. HashBone, a hash-infused pre-roll, is one of the company's signature products in California , and Hollister recently acquired one of Arizona's leading concentrate brands, Venom Extracts, which is coming soon to the California market. This month, Hollister will introduce Easyriders pre-rolls in a collectible tin as the first products from its collaboration with the iconic motorcycle lifestyle magazine. Hollister also has product collaborations with Tommy Chong and the veterans-aligned medicinal brand Tactical Relief.

 

"We are excited to be partnered with Nabis for our last mile fulfillment. Nabis has built a best-in-class last-mile fulfillment business that will help Hollister's brands reach more California dispensaries with reduced lead times," says Carl Saling , the Co-Founder, CEO and Director of Hollister Biosciences.

 

"While Nabis works with a wide range of cannabis brands, we always have our eye on companies with well established and diverse brand portfolios as potential partners," said Jun S. Lee , President of Nabis. "Hollister Cannabis Co. joining our family of Nabis-distributed brands is a great partnership for all parties. We look forward to distributing Hollister's high-profile, top-quality products to dispensaries across California ."

 

  About Nabis  

 

Founded in 2017 by Vince C. Ning and Jun S. Lee , Nabis is a leading cannabis distribution platform with a best-in-class wholesale marketplace that supports the largest portfolio of brands in the world, supplying more than 99% of California's dispensaries with the most diverse selection of innovative products. Nabis offers clients compliant logistics, warehousing, payment collection, financing, sales, and marketing services to accelerate brand growth and access for the largest cannabis market in the world.

 

  Website:   https://www.nabis.com/  

 

   About Hollister Biosciences Inc.   

 

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high-margin model that controls the whole process from manufacture to sales to distribution for what's best described as seed-to-shelf cannabis. Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the first state and locally licensed cannabis company in the city of Hollister, California , birthplace of the "American Biker."

 

  Website:   www.hollisterbiosciences.co  

 

  The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.  

 

  Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on   www.sedar.com  

 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/hollister-biosciences-inc-announces-exclusive-distribution-partnership-with-nabis-for-expanded-market-reach-across-california-301261897.html  

 

SOURCE Hollister Biosciences Inc.

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

 

  Compass management will host a conference call at 8:00 am ET (1:00pm UK)  

 

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×